Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 111

Sort by

Sort Order Select

Journal Articles

How I diagnose and treat thrombocytopenia in geriatric patients

Patrick Foy, Kenneth D. Friedman, Laura C. Michaelis

Blood (2024) 143 (3): 214–223.

https://doi.org/10.1182/blood.2022017634

Published: 2024

Journal Articles

Value of Prophylactic Plasma Treatment and Incidence of Acute Episodes in Patients Enrolled in the International Hereditary Thrombotic Thrombocytopenic Purpura Registry

Blood (2023) 142 (Supplement 1): 691.

https://doi.org/10.1182/blood-2023-184580

Published: 2023

Journal Articles

Insight into the Natural History of Hereditary Thrombotic Thrombocytopenic Purpura: Short- and Long-Term Outcomes in a Longitudinally Followed Large Patient Cohort of the International Hereditary TTP Registry

Blood (2023) 142 (Supplement 1): 4003.

https://doi.org/10.1182/blood-2023-185053

Published: 2023

Journal Articles

Type 2M VWD Laboratory Defects More Consistent Than Bleeding Symptoms across Family Members

Laetitia Faye, Pamela A Christopherson, Sandra L Haberichter, Kenneth D. Friedman, Robert R Montgomery, Veronica H Flood

Blood (2022) 140 (Supplement 1): 8444.

https://doi.org/10.1182/blood-2022-166795

Published: 2022

Journal Articles

Neonatal Exchange Transfusion: When Should We Think about Hereditary Thrombotic Thrombocytopenic Purpura (hTTP)?

Erika Tarasco, Kenneth D. Friedman, James N. George, Paul Knöbl, Ingrid Hrachovinova, Masanori Matsumoto, Reinhard Schneppenheim, Anne Sophie Von Krogh, Bernhard Lammle, Johanna A. Kremer Hovinga Strebel

Blood (2022) 140 (Supplement 1): 336–337.

https://doi.org/10.1182/blood-2022-168612

Published: 2022

Journal Articles

Prevalence of neuropsychiatric symptoms and stroke in patients with hereditary thrombotic thrombocytopenic purpura

Azra Borogovac, Erika Tarasco, Johanna A. Kremer Hovinga, Kenneth D. Friedman, Adam S. Asch, Sara K. Vesely, Calin I. Prodan, Deirdra R. Terrell, James N. George

Blood (2022) 140 (7): 785–789.

https://doi.org/10.1182/blood.2022016044

Published: 2022

Includes: Supplemental data

Journal Articles

Prevalence of Stroke and Cognitive Impairment in Patients with Hereditary Thrombotic Thrombocytopenic Purpura

Azra Borogovac, Erika Tarasco, Johanna A. Kremer Hovinga Strebel, Kenneth D. Friedman, Adam S. Asch, Sara K. Vesely, Calin I. Prodan, James N. George

Blood (2021) 138 (Supplement 1): 1008.

https://doi.org/10.1182/blood-2021-148714

Published: 2021

Journal Articles

Bleeding in Patients with Clinically Severe Von Willebrand Disease: Interim Analysis of Athn 9: A Natural History Study for People with Severe Von Willebrand Disease (VWD)

Angela C. Weyand, Martin Chandler, Carol Fedor, Kenneth D. Friedman, Sweta Gupta, Kristina M. Haley, Chunla He, Nikki Hirsh, Salley Pels, Jonathan C. Roberts, Tung T. Wynn, Robert F. Sidonio, Jr.

Blood (2021) 138 (Supplement 1): 3183.

https://doi.org/10.1182/blood-2021-145631

Published: 2021

Journal Articles

Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura

Erika Tarasco, Lukas Bütikofer, Kenneth D. Friedman, James N. George, Ingrid Hrachovinova, Paul N. Knöbl, Masanori Matsumoto, Anne Sophie von Krogh, Isabella Aebi-Huber, Zuzana Cermakova, Magdalena Górska-Kosicka, Katarzyna A. Jalowiec, Carlo R. Largiadèr, Zoltán Prohászka, György Sinkovits, Jerzy Windyga, Bernhard Lämmle, Johanna A. Kremer Hovinga

Blood (2021) 137 (25): 3563–3575.

https://doi.org/10.1182/blood.2020009801

Published: 2021

Includes: Supplemental data

Journal Articles

Redefining outcomes in immune TTP: an international working group consensus report

Adam Cuker, Spero R. Cataland, Paul Coppo, Javier de la Rubia, Kenneth D. Friedman, James N. George, Paul N. Knoebl, Johanna A. Kremer Hovinga, Bernhard Lӓmmle, Masanori Matsumoto, Katerina Pavenski, Flora Peyvandi, Kazuya Sakai, Ravi Sarode, Mari R. Thomas, Yoshiaki Tomiyama, Agnès Veyradier, John-Paul Westwood, Marie Scully

Blood (2021) 137 (14): 1855–1861.

https://doi.org/10.1182/blood.2020009150

Published: 2021

Includes: Supplemental data

Journal Articles

Bleeding in Patients with Clinically Severe Von Willebrand Disease: Preliminary Results of Athn 9, a Natural History Study of the Safety, Effectiveness, and Practice of Treatment for People with Severe Von Willebrand Disease (VWD)

Angela C. Weyand, MD, Kenneth D Friedman, MD, Sweta Gupta, MD, Kristina M. Haley, DO, Chunla He, Salley Pels, MD, Jonathan C. Roberts, MD, Crystal Watson, BS, Robert F. Sidonio, Jr., MD MSc.

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-137124

Published: 2020

Journal Articles

U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Association between Family History and Age of Diagnosis

Courtney D Thornburg, MD, Kenneth D Friedman, MD, Michael F Guerrera, MD, Chunla He, Lynn M Malec, MD, Mindy L Simpson, MD, Michael D Tarantino, MD, H. Marijke Van Den Berg, Crystal Watson, BS, Shannon L Carpenter, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-138748

Published: 2020

Journal Articles

Identification of Copy Number Variants in Type 1 and Type 3 VWD by aCGH in the Zimmerman Program

Pamela A Christopherson, Rupa A Udani, PhD, Crystal Perry, BS, Daniel B Bellissimo, PhD, Sandra L Haberichter, PhD, Veronica H Flood, MD, Kenneth D Friedman, MD, Joan Cox Gill, MD, Robert R. Montgomery, MD, Zimmerman Program Investigators

Blood (2016) 128 (22): 872.

https://doi.org/10.1182/blood.V128.22.872.872

Published: 2016

Journal Articles

Von Willebrand Factor (VWF) Propeptide and Factor VIII (FVIII) Levels Identify the Contribution of Decreased Synthesis and/or Increased Clearance Mechanisms in the Pathogenesis of Type 1 Von Willebrand Disease (VWD) in the Zimmerman Program

Sandra L Haberichter, PhD, Pamela A Christopherson, Veronica H Flood, MD, Joan Cox Gill, MD, Kenneth D Friedman, MD, Robert R. Montgomery, MD

Blood (2016) 128 (22): 874.

https://doi.org/10.1182/blood.V128.22.874.874

Published: 2016

Journal Articles

Pathways Relevant to AML Pathogenesis Targeting the Hematopoietic-Specific Cebpa +37 Kb Enhancer

Stacy Cooper, MD, Hong Guo, MD PhD, Justin Thomas, Jay L. Hess, MD PhD, Peter D. Aplan, MD, Donald Small, MD PhD, Alan D. Friedman, MD

Blood (2016) 128 (22): 2691.

https://doi.org/10.1182/blood.V128.22.2691.2691

Published: 2016

Journal Articles

Laboratory-Developed MLPA ® Probes Enable CNV Detection in the CFHR4 Gene to Aid aHUS Genetic Evaluation

Kevin Pirelli, BS, Curt Czajkowski, BS, MT(ASCP), Veronika Mladenova, BS, Stefanie Dugan, MS, CGC, Valerie Trapp-Stamborski, PhD, Kenneth D Friedman, MD, Rupa A Udani, PhD

Blood (2016) 128 (22): 1361.

https://doi.org/10.1182/blood.V128.22.1361.1361

Published: 2016

Journal Articles

Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States

Blood (2016) 127 (20): 2481–2488.

https://doi.org/10.1182/blood-2015-10-673681

Published: 2016

Includes: Supplemental data

Journal Articles

Prevalence of Low VWF, VWD, and Isolated Collagen Binding Defects in Subjects Undergoing Evaluation for VWD

Sandra L Haberichter, PhD, Tricia L Slobodianuk, Andrew Podd, Kenneth D Friedman, MD, Veronica H Flood, MD

Blood (2015) 126 (23): 1090.

https://doi.org/10.1182/blood.V126.23.1090.1090

Published: 2015

Journal Articles

In Vivo Deletion of the Cebpa +37 Kb Enhancer Markedly Reduces Cebpa mRNA in Myeloid Progenitors but Not in Non-Hematopoietic Tissues to Impair Granulopoiesis

Alan D. Friedman, MD, Hong Guo, MD PhD, Stacy Cooper, MD

Blood (2015) 126 (23): 1178.

https://doi.org/10.1182/blood.V126.23.1178.1178

Published: 2015

Journal Articles

Evaluation of a Standardized Approach to the Diagnosis of Mild Platelet Function Defects: Recommendation for a Targeted Approach to the Diagnosis of Mild Platelet Function Defects and Identification of a Subset of Children with a "Developmental" Form

Jessica A Lake, MD MPH, Kenneth D Friedman, MD, Veronica H Flood, MD, Shawn M Jobe, MD PhD, Rowena Punzalan, MD, Joan Cox Gill, MD

Blood (2015) 126 (23): 1052.

https://doi.org/10.1182/blood.V126.23.1052.1052

Published: 2015

NARROW

How I diagnose and treat thrombocytopenia in geriatric patients

Value of Prophylactic Plasma Treatment and Incidence of Acute Episodes in Patients Enrolled in the International Hereditary Thrombotic Thrombocytopenic Purpura Registry

Insight into the Natural History of Hereditary Thrombotic Thrombocytopenic Purpura: Short- and Long-Term Outcomes in a Longitudinally Followed Large Patient Cohort of the International Hereditary TTP Registry

Type 2M VWD Laboratory Defects More Consistent Than Bleeding Symptoms across Family Members

Neonatal Exchange Transfusion: When Should We Think about Hereditary Thrombotic Thrombocytopenic Purpura (hTTP)?

Prevalence of neuropsychiatric symptoms and stroke in patients with hereditary thrombotic thrombocytopenic purpura

Prevalence of Stroke and Cognitive Impairment in Patients with Hereditary Thrombotic Thrombocytopenic Purpura

Bleeding in Patients with Clinically Severe Von Willebrand Disease: Interim Analysis of Athn 9: A Natural History Study for People with Severe Von Willebrand Disease (VWD)

Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura

Redefining outcomes in immune TTP: an international working group consensus report

Bleeding in Patients with Clinically Severe Von Willebrand Disease: Preliminary Results of Athn 9, a Natural History Study of the Safety, Effectiveness, and Practice of Treatment for People with Severe Von Willebrand Disease (VWD)

U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Association between Family History and Age of Diagnosis

Identification of Copy Number Variants in Type 1 and Type 3 VWD by aCGH in the Zimmerman Program

Von Willebrand Factor (VWF) Propeptide and Factor VIII (FVIII) Levels Identify the Contribution of Decreased Synthesis and/or Increased Clearance Mechanisms in the Pathogenesis of Type 1 Von Willebrand Disease (VWD) in the Zimmerman Program

Pathways Relevant to AML Pathogenesis Targeting the Hematopoietic-Specific Cebpa +37 Kb Enhancer

Laboratory-Developed MLPA ® Probes Enable CNV Detection in the CFHR4 Gene to Aid aHUS Genetic Evaluation

Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States

Prevalence of Low VWF, VWD, and Isolated Collagen Binding Defects in Subjects Undergoing Evaluation for VWD

In Vivo Deletion of the Cebpa +37 Kb Enhancer Markedly Reduces Cebpa mRNA in Myeloid Progenitors but Not in Non-Hematopoietic Tissues to Impair Granulopoiesis

Evaluation of a Standardized Approach to the Diagnosis of Mild Platelet Function Defects: Recommendation for a Targeted Approach to the Diagnosis of Mild Platelet Function Defects and Identification of a Subset of Children with a "Developmental" Form

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only